Edition:
United States

Chembio Diagnostics Inc (CEMI.OQ)

CEMI.OQ on NASDAQ Stock Exchange Capital Market

6.85USD
2 Dec 2016
Change (% chg)

-- (+0.00%)
Prev Close
$6.85
Open
$6.85
Day's High
$6.90
Day's Low
$6.80
Volume
1,418
Avg. Vol
13,743
52-wk High
$9.32
52-wk Low
$4.03

CEMI.OQ

Chart for CEMI.OQ

About

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies,... (more)

Overall

Beta: 0.84
Market Cap(Mil.): $83.59
Shares Outstanding(Mil.): 12.03
Dividend: --
Yield (%): --

Financials

  CEMI.OQ Industry Sector
P/E (TTM): -- 29.13 29.87
EPS (TTM): -1.15 -- --
ROI: -60.38 15.56 14.95
ROE: -60.38 16.69 16.29

BRIEF-Chembio Diagnostics Q3 loss per share $0.19

* Chembio diagnostics reports third quarter 2016 financial results

Nov 10 2016

BRIEF-Chembio to acquire RVR diagnostics, establish operations in Southeast Asia

* Chembio agrees to acquire Malaysia-based RVR Diagnostics and establish operations in Southeast Asia

Nov 04 2016

BRIEF-Chembio agrees to acquire Malaysia-based RVR Diagnostics

* Chembio agrees to acquire Malaysia-based RVR Diagnostics and establish operations in Southeast Asia

Nov 04 2016

BRIEF-Chembio's DPP Zika test approved by Brazil'S Health Regulatory Agency

* Chembio's DPP Zika test approved by Brazil'S health regulatory agency

Nov 01 2016

BRIEF-Chembio awarded $330,000 contract

* Awarded CDC contract for Zika, Dengue, and Chikungunya surveillance testing in India, Peru, Guatemala and Haiti Source text for Eikon: Further company coverage:

Sep 28 2016

BRIEF-Chembio expands exclusive distribution agreements with Isla Lab to include Puerto Rico and U.S. Virgin Islands

* Chembio expands exclusive distribution agreements with Isla Lab to include Puerto Rico and U.S. Virgin Islands

Sep 23 2016

BRIEF-Chembio enters into exclusive agreement with Isla Lab

* Chembio expands product distribution through exclusive agreement with Isla Lab in the Caribbean

Aug 18 2016

BRIEF-Chembio Diagnostics Q2 loss per share $0.86

* Q2 revenue fell 51.4 percent to $3.27 million Source text for Eikon: Further company coverage:

Aug 11 2016

BRIEF-Chembio Diagnostics announces upsizing and pricing of public offering of common stock

* Announces upsizing and pricing of public offering of common stock

Jul 29 2016

BRIEF-Chembio's Zika test cleared for sale in Europe and Caribbean

* Chembio's DPP Zika IgM/IgG assay obtains CE mark for rapid point-of-care detection of Zika virus Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jul 27 2016

Competitors

Earnings vs. Estimates